Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedDec 24, 2025
DataAggregated Company Financials
Companies5
  • 7D5.8%
  • 3M8.0%
  • 1Y14.3%
  • YTD11.2%

The Biotech industry is up 2.0% in the last week, with Genmab up 6.9%. This means that the industry has gained 12% over the past year. In the next few years, earnings are forecast to decline by 12% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Dec 2025DKK 180.1bDKK 40.5bDKK 18.9b6.1x9.5x4.4x
Fri, 21 Nov 2025DKK 174.1bDKK 41.0bDKK 19.2b6x9.1x4.2x
Sun, 19 Oct 2025DKK 180.0bDKK 38.9bDKK 16.8b13.1x10.7x4.6x
Tue, 16 Sep 2025DKK 158.5bDKK 38.7bDKK 16.7b12.6x9.5x4.1x
Thu, 14 Aug 2025DKK 131.9bDKK 29.6bDKK 8.8b12.1x15x4.5x
Sat, 12 Jul 2025DKK 127.6bDKK 26.9bDKK 7.3b11.3x17.4x4.7x
Mon, 09 Jun 2025DKK 137.5bDKK 27.5bDKK 7.5b11.3x18.3x5x
Wed, 07 May 2025DKK 132.1bDKK 27.3bDKK 7.7b11.7x17.2x4.8x
Fri, 04 Apr 2025DKK 126.8bDKK 27.3bDKK 7.7b11.2x16.5x4.6x
Sun, 02 Mar 2025DKK 162.8bDKK 27.7bDKK 7.8b12.4x20.8x5.9x
Tue, 28 Jan 2025DKK 166.7bDKK 26.0bDKK 4.7b16.9x35.5x6.4x
Thu, 26 Dec 2024DKK 160.6bDKK 26.0bDKK 4.7b16.6x34.2x6.2x
Sat, 23 Nov 2024DKK 161.9bDKK 26.0bDKK 4.7b17x34.5x6.2x
Mon, 21 Oct 2024DKK 174.2bDKK 25.5bDKK 5.5b21x31.8x6.8x
Wed, 18 Sep 2024DKK 197.7bDKK 25.5bDKK 5.5b23.7x36.1x7.8x
Fri, 16 Aug 2024DKK 203.1bDKK 26.0bDKK 5.7b20.1x35.6x7.8x
Sun, 14 Jul 2024DKK 197.3bDKK 24.8bDKK 5.6b17.7x35x8x
Tue, 11 Jun 2024DKK 179.2bDKK 24.8bDKK 5.6b18.3x31.8x7.2x
Thu, 09 May 2024DKK 183.7bDKK 25.2bDKK 6.2b16.1x29.8x7.3x
Sat, 06 Apr 2024DKK 186.1bDKK 23.9bDKK 5.0b19.4x36.9x7.8x
Mon, 04 Mar 2024DKK 184.8bDKK 22.8bDKK 4.3b23.5x43.2x8.1x
Wed, 31 Jan 2024DKK 169.7bDKK 23.3bDKK 4.2b23.2x40.8x7.3x
Fri, 29 Dec 2023DKK 178.0bDKK 23.3bDKK 4.2b26.1x42.8x7.6x
Sun, 26 Nov 2023DKK 172.7bDKK 23.3bDKK 4.2b25x41.5x7.4x
Tue, 24 Oct 2023DKK 163.5bDKK 22.0bDKK 4.7b19x34.5x7.4x
Thu, 21 Sep 2023DKK 202.0bDKK 22.0bDKK 4.7b23.8x42.7x9.2x
Sat, 19 Aug 2023DKK 187.2bDKK 20.6bDKK 3.9b35.3x48.5x9.1x
Mon, 17 Jul 2023DKK 200.5bDKK 19.5bDKK 4.4b40.9x45.5x10.3x
Wed, 14 Jun 2023DKK 207.7bDKK 19.5bDKK 4.4b44.9x47.1x10.6x
Fri, 12 May 2023DKK 218.2bDKK 17.9bDKK 4.1b33.9x53.3x12.2x
Sun, 09 Apr 2023DKK 199.2bDKK 17.9bDKK 3.5b31x56.3x11.1x
Tue, 07 Mar 2023DKK 196.6bDKK 17.9bDKK 3.5b30.3x55.5x11x
Thu, 02 Feb 2023DKK 200.2bDKK 14.7bDKK 3.3b30.7x61.2x13.6x
Sat, 31 Dec 2022DKK 220.4bDKK 14.7bDKK 3.3b34x67.3x15x
Price to Earnings Ratio

67.3x


Total Market Cap: DKK 220.4bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 34.2x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.3x which is lower than its 3-year average PE of 34.3x.
  • The 3-year average PS ratio of 7.6x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 80% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market2.81%
Healthcare5.87%
Biotech5.76%
Biotech5.76%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 2.12k6.9%
+DKK 8.4b		43.0%PE13x
ZEAL Zealand PharmaDKK 483.002.9%
+DKK 941.8m		-32.9%PE5.2x
BAVA Bavarian NordicDKK 189.453.2%
+DKK 465.7m		1.0%PE6.1x
STRAP Strategic PartnersDKK 688.001.8%
+DKK 500.5k		-19.1%PB1.6x

Latest News

ZEAL
DKK 483.00
Zealand Pharma
7D
2.9%
1Y
-32.9%
BAVA
DKK 189.45
Bavarian Nordic
7D
3.2%
1Y
1.0%
GMAB
DKK 2,123.00
Genmab
7D
6.9%
1Y
43.0%

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
BIOPOR
DKK 1.04
BioPorto
7D
-2.4%
1Y
-30.2%
STRAP
DKK 688.00
Strategic Partners
7D
1.8%
1Y
-19.1%